Article Details

AstraZeneca further extends clinical trial contract with ImpediMed (ASX:IPD)

Retrieved on: 2022-11-09 04:33:52

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca further extends clinical trial contract with ImpediMed (ASX:IPD). View article details on hiswai:

Excerpt

ImpediMed (ASX:IPD) has extended its clinical trial contract with AstraZeneca for the third time.

Article found on: themarketherald.com.au

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up